-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $18

Benzinga·12/12/2025 11:19:33
Listen to the news
HC Wainwright & Co. analyst Sean Lee maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and raises the price target from $13 to $18.